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Abstract: The feasibility and the clinical value of the enzyme-multiplied immunoassay technique (EMIT) monitoring of
blood concentrations of cyclosporine A (CsA) in patients treated with CsA were investigated after kidney transplantation.
The validation method was performed, to the EMIT determination of CsA blood concentration. the CsA whole blood
•trough concentrations (Co) of patients in different time periods after renal transplantation were monitored. and combined
with the clinical complications. the statistical results were analyzed and compared. EMIT was precise. accurate and
stable. also with a high quality control. The mean postoperative blood concentration of CsA was as follows: <1 month.
(281.4 ± 57. 9)nglmL; 2 - 3 months. (264.5 ± 41. 2) nglmL; 4 - 5 months. (236.4 ± 38.9) nglmL; 6 - 12 months.
(206.5 ± 32. 6)nglmL; >12 months. (185.6 ± 28.1)nglmL. The toxic reaction rate of CsA blood concentration within
the recommended therapeutic concentration was 14. 1%. significantly lower than that of the none-recommended dose
group (37.2%) (P<0.05); the transplantation rejection rate was 4.4%. significantly lower than that of the none-
recommended dose group (22.5%) (P<0.05). Using EMIi to monitor the blood concentration of CsA as the routine
laboratory method is feasible. and is able to reduce the CsA toxicity and rejection significantly. leading to achieving the
desired therapeutic effect.
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1 Introduction
Cyclosporine A (CsA) is an effective immunosuppressant.
which is able to inhibit helper T lymphocytes and the activity
of B lymphocytes specifically. It is widely used in the immu-
nosuppressive therapy of patients after renal transplantation
and the inhibition of allograft rejection. The clinical appli-
cation of CsA is a new milestone in the modern transplanta-
tion [1,2]. CsA's main toxic reactions include liver toxicity
and kidney toxicity, and the long-term renal toxicity can
lead to chronic allograft nephropathy (CAN), affecting the
graft survival [3]. These side effects are closely related to
the CsA blood concentration, but the reduction of CsA dos-
age will lead to rejection, particularly a higher rejection, 4
to 6 months after transplantation [4]. Because of the large
individual differences in CsA bioavailability and pharmaco-
kinetics, the therapeutic window is narrow, and to make a
distinction between the renal toxicity and the rejection after
the renal transplantation is difficult. The regular clinical
monitoring of blood trough concentrations of CsA is able to
help adjust the dosage to reduce the incidence of acute
rejection and the rejection degree and to suggest a toxic
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dosage, thus reducing the incidence of liver and renal toxic-
ity [5].
Currently. the commonly used determination methods of
CsA concentrations in plasma include immunoassay and
high performance liquid chromatography (HPLC). HPLC
uses chromatographic separation to determine the concen-
trations of CsA parent drug and metabolites, with advanta-
ges like a strong specificity, a high sensitivity and a wide
linear range (50 -1500 nglmL). etc. Its selectivity. preci-
sion and accuracy are high, and it is a reference method for
the evaluation of other methods [6]. The main disadvantages
are: very tedious and time-consuming sample preparation, a
larger sample size (about 1 mL), and a low sample recovery
rate, and experienced personnel is needed, and therefore.
it is not suitable for determining bulk samples [7]. EMIT is
a homogeneous enzyme immunoassay technique. whose
determination is based on the antibody's combining sites
competed for by the drugs in the sample and the drugs la-
beled by glucose 6-phosphate dehydrogenase (G;PDH).
Combined with the antibody, the, enzyme activity decreases.
and based on the activity of enzyme, the concentration of
analytes in the sample is determined, and the active enzyme
transfers the oxidized nicotine adenine dinucleotide (NAD)
into the reduced NAD, resulting in the absorbance changes•
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so the spectrophotometric measurement should be used. The
results of 145 CsA samples were compared between Cloned
Enzyme Drugs Immunoassay(CEDIA, IDx), Auorescence
Polarization Immunoassay (FPIA, AxSYM) , EMIT and
HPLC methods. EMIT and HPLC are best correlated.
EMIT and HPLC have the minimum deviation [8,9].
EMIT has a high degree of automation, with a short meas-
urement period, which is suitable for determining the ther-
apeutic concentration and the toxicity range of CsA. There-
fore, it may be considered to monitor large quantities of
clinical CsA samples.
2 Materials and methods
2.1 General infonnation
90 males, with a mean age of (38.4 ± 11. 42)years, a mean
lxxly weight of (62.3±7.82)kg, and 486 times of monito-
ring; 72 females, with a mean age of (43.6 ± 10.35) years,
a mean lxxly weight of (54.2 ± 8. 26)kg, and 269 times of
monitoring.
2.2 Medication scheme
The triple immunosuppressive scheme, cyclosporine A
(CsA) + prednisone (Pred) + mycophenolate mofetil (MMF),
was adopted for the elected patients. In addition, the adju-
vant drugs included Hexinshuang, Bailing capsule, liver-
protective and treating drugs.
2.3 Detennination of plasma concentration
After the patients took the medicine for 3 d after the opera-
tion and. showed a steady state, 2 mL of venous blood was
collected before taking medicine, and Viva detector and
Emit 2000 Cyclosporine Specific Assay kit (Dade Behring,
Inc., United States) were applied, and following the
routine operation, EMIT was used to determine the whole
blood CsA trough concentration (Co). Patients with an
acute rejection were excluded.
2.4 Frequency monitoring and sample collection
The monitoring of plasma concentration started one week
after the surgery, once every week within 1 month, once
every 2 weeks within 2 to 3 months, and a regular monthly
monitoring after 3 months. Liver and kidney function or
any abnormal clinical manifestations were monitored as
needed. Monitoring frequency of long-term survival
patients could be lower. 2 mL of venous blood was collected
before taking the medicine in the morning, with heparin
anticoagulation.
2.5 Statistical analysis
ANOVA and chi-square test were used in the statistical
treatment. P<0.05 was considered statistically si~ificant.
SPSS 13.0 was adopted in the statistical analysis.
3 Results
3.1 Detennination of precision and accuracy with EMIT and
stability test
The relative standard deviation (RSD) of intra-day and in-
ter-day variation of CsA quality control materials with
high, middle and low concentrations was within ± 8%; the
recovery rate was around 100% (Table 1). The stability
was investigated after the quality control solutions at three
concentration levels kept at room temperature for 24 h, and
frozen for 7 d at - 30 ·C, repeatedly frozen and thawed
once or twice, and the results showed no significant
change, RSD <13%.
Thble 1 Precision and accuracy of the concentration of CsA by EMIT
C,
Intra-day Inter-day
Recovery rateNo. Measured value Measured value(nglmL) (nglmL) RSD (%) (nglmL) RSD (%) (%-)
1 74.0 75.4±2.3 3.05 76.1±5.8 7.62 lO1.6±2.8
2 168.0 171.3±3.6 "2.10 164.3±9.6 5.84 98.4±2.3
3 465.0 464.6±9.5 2.04 484.4 ± 28. 5 5.88 99.7±3.2
c" the whole blood trough concentration; RSD, the relative standard deviation.
Time after surgery Case-times Dose[mg/(kg'd)] Co(nglmL)
(month)
1lIbIe 2 The relationship between CsA dose and concentration at dif-
ferent time after renal transplantation
c" the whole blood trough concentration.
3.2 Detennination of CsA whole blood trough concentratiom
of patients after renal tr'amplantation in different groups
Groups were divided based on the different time lengths
after the patients received the renal transplantation, and
CsA doses taken by different groups of renal transplant
recipients and the mean value and standard deviation of the
whole blood trough concentrations were calculated
(Table 2).
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After renal transplantation, the superiority of the triple-
based immunosuppressive medication scheme with CsA as
the chief drug has been widely recognized by transplanta-
tion specialists, but because of the different initial doses and
the different reduction schemes in different units, there has
been no uniform therapeutic window concentration at home
and abroad. In this study, the whole blood trough concen-
tration values of CsA of 162 renal transplanted recipients
who had received CsA immunosuppressive therapy were de-
termined for 755 case-times. The CsA trough concentra-
tions in different periods were lower than those reported in
the literature, which may be related to the different deter-
mination methods in different centers, but the rejection and
toxicity of patients with CsA therapy after renal transplan-
tation in our center were lower than those reported at home
and abroad [10-13], indicating that the therapeutic window
set in our center is reasonable.
The most widely used determination method of plasma
concentration is HPLC [14], but because of its complicated
procedures and long determining period, and high technical
requirements, it is difficult to be widely used in clinic. In
the EMIT used in our center, VIVA automatic immune
analyzer was used, with an automatic sampling system, a
good temperature control system and a data processing and
storage device. It has the advantages like high degree of au-
tomation, fewer samples and no need of sample pretreat-
ment, so it is suitable for emergency cases and the analysis
and determination of a large sample [15]. We performed a
method validation for CsA determination with EMIT, and
the results showed that, as long as the operating rules were
followed, the quality control standards analyzed, and the
precision, accuracy and stability met the measurement
requirements, the quality control results would be good.
EMIT for routine clinical testing of CsA blood concentra-
tion is feasible.
The individual differences of CsA plasma concentration
are huge, and different patients show different effective
plasma concentrations. It is prone to have rejection and
toxic reactions, which is related to such influencing factors
as the medication time period after transplantation, physi-
cal condition, age, liver and kidney function, food, and
combined drug therapy [16]. CsA nephrotoxicity is dose-
dependent, and < 400 nglmL whole blood concentration
may effectively prevent the incidence of renal toxicity.
Therefore, ~ 400 nglmL whole blood CsA concentration is
generally considered as the boundary of toxic and non- toxic.
<100 nglmL whole blood CsA levels are considered as un-
der-dose, and 100 - 400 nglmL whole blood CsA concen-
trations are defined as treatment doses. In the group of 755
case-times of monitoring plasma concentrations, the vast
majority of the patients taken medicine for longer than 2
months after renal transplantation showed a more stable
Thble 4 The relationship between CsA concentration and toxicity at
different time after transplantation
Time after Case- Co Toxicity No toxicity X' P valuesurgery (month) times (ng/mL) ( times) (times)
<1 181 ~4oo 13 21 7.50 <0.05
<400 25 122
2-3 261 ~36O 18 24 14.99 <0.05
<360 36 183
4-5 165 ~36O 12 31 6.47 <0.05
<360 14 108
6-12 98 ~280 12 27 14.37 <0.05
<280 2 57
>12 50 ~250 12 10 9.18 <0.05
<250 4 24
c" the whole blood trough concentration.
3.4 The relati~hip between whole blood trough concentra-
tion of CsA and liver and kidney toxicity
With CsA blood concentrations of 400, 360, 360, 280 and
250 nglmL as the reference limits of toxic reactions respec-
tively, the toxic reaction rate of each group was analyzed.
When the CsA blood concentration was higher than the ref-
erence limits, the toxic reaction rates were 38.2%, 42.9%,
27.9%, 30.8% and 54.5%, respectively, with a mean tox-
ic reaction rate of 37.2% (67 case- times); when lower than
the reference limits, the mean toxic reaction incidence rate
was 14.1 % (81 case-times), as shown in Table 4.
Thble 3 The relationship between CsA concentration and rejection at
different time after transplantation
Time after Case- Co Rejection No rejection , P value
surgery (month) times (ng/mL) (n) (n) X
181 :(;210 25 57 16.90 <0.05<1
>210 7 92
2-3 261 :(;210 16 73 14.12 <0.05
>210 7 165
4-5 165 :(;140 9 50 4.22 <0.05
>140 6 100
6-12 98 :(;120 6 17 12.74 <0.05
>120 1 74
>12 50 :(;100 2 3 5.67 <0.05
>100 1 44
c" the whole blood trough concentration.
3.3 The relationship between the whole blood trough concen-
tration of CsA and the rejection 4 Discussion
With CsA plasma concentrations of 210, 210, 140, 120 and
100 nglmL as the reference limits respectively, the rejec-
tion in each group was analyzed. When the CsA plasma
concentration was lower than the reference limits of rejec-
tion, the rejection rates were 32. 5%, 18. 0%, 18. 0%,
26.1 % and 66.6%, respectively, with an average rate of
22.5%; when it was higher than the reference limits of the
rejection, the mean rejection rate was 4.4% (Table 3).
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plasma concentration. If the plasma concentration of CsA
was adjusted to the recommended therapeutic concentration
range, the toxic reaction rate was 14.1%, and the rejection
rate was 4.4%. In the non-regular group with a concentra-
tion higher than the recommended therapeutic range, the
toxic reaction rate was 37.2%, while with a concentration
lower than the range, the rejection rate was 22.5%. The
clinical manifestations of toxic effects include gingival
swelling, and an increase of alanine aminotransferase, cre-
atinine, urea nitrogen, and uric acid in the laboratory tests.
In this group, through the timely adjustment of the dosage,
all were reduced to or reached the effective concentration,
with no new rejection nor severe poisoning phenomenon.
CsA was significantly time- and dose-dependent, and in this
group of patients, with the prolonging of the postoperative
time, CsA dose was gradually reduced, usually 6 - 8
mg/(kg'd) within 6 months after the operation, 3 - 6 mg/
(kg'd), 12 months, and 2 - 5 mg/(kg'd), more than one
year. Basically, CJ also showed a downward trend with the
prolonging of the postoperative time, with no more
change, >6 months. The ideal concentration range of CsA
treatment after renal transplantation in the triple immuno-
suppressive therapeutic scheme recommended by our center
is: <1 month: 210-400ng/mL; 2-3 months: 210-360
ng/mL; 4 - 5 months: 140 - 360 ng/mL; 6 - 12 months:
120 - 280 ng/mL; >12 months: 100 - 250 ng/mL. In this
group, the mean CsA plasma concentration of the patients
in each period was within the effective concentration
range, which ensured the satisfying immunosuppressive
effects, and also reduced the incidence of the toxic effect
and rejection reaction of CsA, indicating that the applica-
tion of regular monitoring of CsA in the renal transplant
recipients and the blood trough concentration monitoring in
our center are reasonable.
In conclusion, the regular monitoring of plasma concen-
tration of CsA and the adjustment of clinical dose according
to individual patients show important clinical significance in
improving kidney transplant success rate and the life quality
of the patients. The routine laboratory determination of
CsA plasma concentration with EMIT is practicable. Medi-
cation of CsA based on the monitoring results and the rec-
ommended therapeutic concentration range is able to reduce
CsA toxicity and rejection reaction significantly, achieving
a more satisfactory therapeutic effect.
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